Esperion Therapeutics

ESPR

Market cap $868M

Esperion Therapeutics, Inc. ( ESPR ) Jefferies London Healthcare Conference 2025 November 18, 2025 3:00 AM EST Company Participants Benjamin Halladay - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Good morning. Welcome to the Jefferies London Healthcare Conference.

ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company's partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for NILEMDO is expected in Q2 2026.

Esperion Therapeutics, Inc. and C4 Therapeutics, Inc. were among the top contributors to performance. SiTime Corp. was also a top contributor. The company provides silicon timing chips for a wide range of electronics. The greatest detractor from Fund performance for the quarter was Monday.com Ltd.

Esperion Therapeutics, Inc. ( ESPR ) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health November 11, 2025 2:00 PM EST Company Participants Sheldon Koenig - President, CEO & Director LeAnne Bloedon Conference Call Participants Dharmesh Patel Fatima Rodriguez Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Jason Zemansky - BofA Securities, Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Presentation Operator Good day, everyone.

Esperion Therapeutics remains a buy despite market skepticism, recent stock offering, and underwhelming Q3 earnings, supported by strong cardiovascular drug franchises. ESPR's profitability timeline is intact, but execution is critical; Q4 results are a key 'prove it' moment as the company targets sustained profitability and margin improvements. Valuation is attractive with double-digit revenue growth, reasonable price/sales ratios, and upcoming milestone payments and royalties from global partnerships, especially in Japan and Europe.

Esperion's Q3 loss widens despite a 69% jump in revenues. Mixed results and investor jitters probably drag ESPR shares down 15%.

ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 4, 2025, the Company granted 23 new employees 77,650 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.

Esperion Therapeutics, Inc. ( ESPR ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Alina Venezia Sheldon Koenig - President, CEO & Director Benjamin Halladay - Chief Financial Officer Lisa Schafer Conference Call Participants Georgia Bank - Jefferies LLC, Research Division Jason Zemansky - BofA Securities, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Serge Belanger - Needham & Company, LLC, Research Division Sara Nik - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Hello, ladies and gentlemen, and thank you for standing by.

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.15 per share a year ago.

– Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance –